Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway

Overview of attention for article published in Frontiers in Pharmacology, July 2024

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter: 2 X users

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 6,521 followers.

RT @FrontPharmacol: New Research: Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-smal…

01 Aug 2024

Reply Repost Favourite

New Research: Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway https://t.co/OI8n3GTTqu #FrontiersIn #Pharmacology

31 Jul 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.